UroGen Pharma announces CMS assigned permanent HCPCS code for ZUSDURI

UroGen Pharma (URGN) announced that the Centers for Medicare and Medicaid Services, CMS, has assigned a permanent Healthcare Common Procedure Coding System, HCPCS, Level II J Code, J9282, for ZUSDURI for intravesical solution, the first and only FDA-approved medicine for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, LG-IR-NMIBC. The J Code will be effective January 1, 2026, and is intended to facilitate standardized billing and claims submission across hospital outpatient departments and physician office settings.